LTR Pharma Receives Manufacturing Validation for SPONTAN Bioequivalence Study; Shares Down 3%
LTR Pharma Receives Manufacturing Validation for SPONTAN Bioequivalence Study; Shares Down 3%
LTR Pharma 获得 SPONTAN 生物等效性研究的制造验证;股价下跌3%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册